Celldex Therapeutics
CLDX
27.42
-0.54
-1.93%
Celldex Therapeutics
US · CLDX
#2630 by market cap
Listed 1970
27.42
-0.54
-1.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
C+
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Barclays moved from Sell to Buy on 2026-04-20.
Analyst consensus 11 analysts
Buy
Avg price target 67.18 +145.0%
Price target rangecurrent 27.42
Low29.00
Avg67.18
High100.00
Buy 91%
Hold 9%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-09 | CCORF | -- | Buy | 68.00 |
| 2026-11-09 | Morgan Stanley | -- | Buy | 61.00 |
| 2026-11-06 | Stifel | -- | Buy | 68.00 |
| 2026-11-06 | Goldman Sachs | -- | Hold | 29.00 |
| 2026-11-06 | Guggenheim | -- | Buy | 100.00 |
| 2026-11-06 | H.C. Wainwright | -- | Buy | 64.00 |
| 2026-11-06 | Barclays | -- | Buy | 53.00 |
| 2026-11-05 | Cantor Fitzgerald | -- | Buy | 72.00 |
| 2026-10-20 | Morgan Stanley | -- | Buy | 57.00 |
| 2026-10-15 | Wells Fargo | -- | Buy | 72.00 |
| 2026-10-13 | Cantor Fitzgerald | -- | Buy | 72.00 |
| 2026-10-05 | H.C. Wainwright | -- | Buy | 64.00 |
| 2026-10-03 | LifeSci Capital | -- | Buy | 64.00 |
| 2026-10-02 | H.C. Wainwright | -- | Buy | 64.00 |
| 2026-09-28 | LifeSci Capital | -- | Buy | 64.00 |
| 2026-09-26 | LifeSci Capital | -- | Buy | 56.00 |
| 2026-09-23 | CCORF | -- | Buy | 60.00 |
| 2026-09-23 | Wells Fargo | -- | Buy | 72.00 |
| 2026-09-23 | Morgan Stanley | -- | Buy | 57.00 |
| 2026-09-23 | Leerink Partners | -- | Buy | 88.00 |
| 2026-09-23 | H.C. Wainwright | -- | Buy | 64.00 |
| 2026-09-22 | Morgan Stanley | -- | Buy | 57.00 |
| 2026-09-22 | Stifel | -- | Buy | 68.00 |
| 2026-09-22 | Guggenheim | -- | Buy | 100.00 |
| 2026-09-22 | H.C. Wainwright | -- | Buy | 64.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-20 | Barclays | Sell → Buy | 45.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2023/Q4 | 2024-02-26 | After close | ±16.09% | +5.83% (in line) |
| 2021/Q4 | 2022-02-28 | After close | ±17.30% | +5.62% (in line) |
| 2020/Q2 | 2020-08-06 | -- | ±33.39% | -4.87% (in line) |
| 2019/Q2 | 2019-08-07 | After close | -- | +2.31% |
| 2018/Q4 | 2019-03-07 | After close | -- | +10.87% |
| 2018/Q2 | 2018-08-08 | After close | -- | -6.76% |
| 2017/Q4 | 2018-03-07 | -- | -- | +11.34% |
| 2017/Q2 | 2017-08-08 | -- | -- | -1.17% |
| 2016/Q4 | 2017-03-14 | After close | -- | +3.33% |
| 2016/Q2 | 2016-08-08 | -- | -- | -3.00% |
| 2015/Q4 | 2016-02-25 | -- | -- | +0.58% |
| 2015/Q2 | 2015-08-10 | After close | -- | -20.56% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Celldex Therapeutics discussion 0 comments